Healthcare stocks were mixed pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.3%.
Greenwich LifeSciences (GLSI) shares were up more than 5% after the company said the European Medicines Agency cleared the use of commercially manufactured GP2 in a phase 3 trial evaluating GLSI-100 to prevent breast cancer recurrence in Europe.